accelerate Good last XXXX everyone. and in expectation us. momentum milestones forth call the multiple the joining our for important year said February, programs, set progress our starting for in our and we the I with progress Thank And our development with thank afternoon, plan maturation quarterly vision When year were you, the Lauren. clinical and you course substantial forward to of I collaborative over that growth alliances. across that and continued organizational with
spread nearly that With including drug of aspect evident in the emergency very rapid development the Dicerna. COVID-XX, every would health public impact a on global thereafter life it including of became scale, and this weeks
of day-to-day measures industry, the to our our we materials fronts aspect the and which are While restrictions our employees like the nearly current think prepare that work us the conduct in am business. once plan, conduct our deliver expectation made move the and within place control most have in otherwise have immediate very adjustments rapidly to our and every has I we source territories put continue all and able in development business we time, clinical on in our to to various lifted ahead work enable world uncertain during and around across that and should work challenging country this proud that trials, dedicated accomplish to highly been of enabled clinical us on to processes, incredible
work. has staggered and been lab been smooth in distancing staff one, whose and on-site and support successful personnel work IT already was appropriate implementing infrastructure schedules work other key for critical With transition and in place, from mid-March the presence remote systems company-wide to we've required a for social
and to this entirety adjust They a ability best uncertainties of inspired team's dedication are this to the has the appreciation of some of the up and that presented. business, pandemic this and make The am the brought Dicerna. has in the finer individuals for of I who quality by experience proud
that our face challenges cash macro the we Despite undoubtedly business are well strong us advancing and position from virus accomplishments. and keep the people position, to our building level, still a on model our to upon recent
was arrangements in of with to early most two these The announcement agreements collaborative of Alnylam our world's portfolio leading the April, biopharmaceutical with of recent adding new some the companies. of
agreements, great candidates reached Dicerna product to ground have for and bring great market, accelerate and companies, With above ability all, new these both outcome Alnylam a a outcome to enhance orphan for our common that but will patients.
clinical these The PH, candidate lead hyperoxaluria, complications kidneys. genetic the to for disorder or the initially pertains manifests of primary of agreements ultra-rare, as our an that nedosiran, in life-threatening treatment first
this therapies non-exclusive, Our each straightforward, arrangement our In terms, with a with agreement for is Alnylam freedom RNAi patent agreement commercialize for to and full has each that respective to respect develop PH. property. ensures our cross-licensing PH party simple portfolios that Alnylam's intellectual to investigational company's relates both and
nedosiran and X, PH in gene X. and gene lumasiran, case, In the X LDHA our Alnylam's X; type which HAOX targets for case, targeting for types the PH
worldwide obligated to on As be single-digit and launch, high Alnylam mid of pay single-digit a royalties sales obligated nedosiran. royalties from this us low to result be Alnylam of sales cross-license, on will lumasiran of pay we will to
candidate pleased PH, to benefit sales differentiated We of or a outcome same to type. financially this patients regardless gratified a and with candidate, benefit rate from be Alnylam's of respectable with the position mutation advancing while the are are very our to in product of intended all at at and time, agreement
our in global to to modality the collaboration with agreement and with second commitment liver commercialization and manifestations treat Alnylam our of development is and disease. The underscores that to population AXAT RNAi a optimal underserved the this patient relates as the patients conviction
currently fibrosis disease to may liver to therapies can manifestations supportive and treat liver with AXAT which liver deficiency is lifestyle and accumulation advanced in genetic no involves management of are disease of causes require approved lead a serious liver a disorder modifications and jaundice, protein care. the There cirrhosis. AXAT, that AXAT transplant. liver, Patients misfolded and
Under molecule, is are Phase liver treatment we a own, clinical deficiency-associated in which, taking for their responsibility of our I/II AXAT agreement candidate ALN-AATXX, disease. the for Alnylam, trial like with our
the timeline agreement, forward to take drug intend Per the we on for the the candidate safety based of development best candidates. two evaluation our patients and these potency, of
post our generated at candidate of territories exercises other on net ultimately on to pay US tiered lead will If the opportunity each its and has is we pivotal commercialization dependent for Dicerna Alnylam commercialization, will opt-in what the ex and royalties rates Alnylam US. candidate, right, selected opt-in in commercialized. product sales development
to that, high first, means low royalties royalties. This would and low high-teens Dicerna double-digit Alnylam would Alnylam pay single-digit to pay we single-digit
If its right, at on a would move rate we Alnylam ex forward. candidate US company also ability commercialization dependent commercialization to opt-in does worldwide in rights we we royalties, another the and commercialization. on would with retain which exchange partner have And milestones not for to
our very the now in to have to respective enhancing of agreements potential pleased for candidates. costly related our to to product And are to litigation place, case the these ability in and cross-license, two IP for We PH putting candidates market. rest orphan the bring accelerating these our
programs. to of the update core provided March, late on and In supporting we response pipeline. our trials our to our on clinical some an pandemic the its Turning impact projected
are as around are coronavirus' of government's and today, some the new in share there execution. updates terms timing world While incremental the impacts and they to vary responses
responses around and to For countries the nedosiran, our globe, local at the time. PHYOXX year. location over multiple for has the pace location to a the enrollment pivotal a albeit outset the varying of clinics' slower Underway responses actions at been PHYOXX virus' in level, to with of trial realities government and continues, than subject at from impact trial
March, for around the each expectations of we of as our gauged enrollment completion first the previous the half. result, of As and, in enrollment the pace expectation at a withdrew sites then-current
effort continuity team local Ralf been maintain clinical for led Rosskamp, site our has an in enrolled top to currently at care at study. each PHYOXX The on and staying investigators, a trial job has with and pivotal remarkable working regulators done of Dicerna, boards the in review situation institutional of of patients by
protocol and nurse-administered, investigators, emergency with April. implementing amendments allow to study to dosing in this been safety began which with continue have follow-ups home-based telehealth We patients
in of previously all patients efforts, these result enrolled remained trial. a the have As
open Full enrollment of resumption sooner than basis will as up be others. will areas some on a site-by-site
of As to sites starting begun to have see steps take and impacted screening certain today, sourcing virus' the patients. we earlier spread continue possible PH to in
online and locations we US key back few be next enrolling could As weeks. of within and the European believe now, certain
to NDA yet too enrollment revised That soon submission provide the PHYOXX completion to said, for ascertain timeline of estimate it or to our impact a timing. is
greater clarity. to and continue will provide update an when have situation monitor So, the we we closely
PHYOXX, of initiation. Also expect year, initiation half do to planned our trials, second PHYOXX planned to and in we are impacted namely and approvals. each PHYOXX which to by expected PHYOXX had and the COVID-XX supplemental we half; we begin not our the time, as to is first gauging in planned were for this initiate PHYOXX, be initiate At of subject originally PHYOX which will able this options regulatory PHYOXX and
time, will we believe current for be inclusion data from studies these that NDA. in At the the available
potential as studies these on nonetheless nedosiran they they of continued required characterizing but helpful submission, for of and are label. none drug bear are us However, to studies the to NDA are interest may
reliable expectation starts. it for all, too For give study early to is
So, initiate PHYOXX, update feasible to line the sight to as situation, an when a have with timing. and to clearer we'll monitor do can what we on continue provide prepare we when of
required future and PHYOXX having all home-based arrangement site dose most due Our to to follow-up visits. investigators by telehealth nearly with patients an safety who restrictions continues administration multi-dose, long-term for transitioned alternate trial now progress to dosing
we that X, in enrolled were had included As patients in analysis. March of patients XX results up interim May from our XX PHYOXX,
nonetheless interim and the rollover, the study, expand more once-monthly from will trial, but are results safety long-term, a analysis time March. the in by efficacy in elapses only into nedosiran as we As with greater very multi-dose PHYOXX encouraged first saw we open-label, administration visibility
trial. are and patients for generally patient PHYOXX and All injection type on oxalate events. site of at X one At least least in no drug-related two been levels tolerated patient. who the had four visits a dosed two X near-normal the patients adverse had nearly months, severe time, and urinary at with nedosiran years four normal reached appear three Of well three which reactions or exposure had that no total type
this will now conference, taking in OxalEurope, first planned originally the medical year, The place December. for half be
plan from more to to mature present So, a instead for and should relative provide we own our planned Day our with as much us which March. August, of in and R&D of to of present set interim results data our the data venue, timing move that forward on robust part PHYOXX preliminary
and place out that we planned in a commercial nedosiran of launch key key for put roll preparation we are From for standpoint, hire the continuing continue to and roles. will need infrastructure selectively to
we Clearly, an mind to forward of visibility pace submission hiring at slower team milestones. continuing on key the will we the on are to we ahead timing we are to and what clarity so times, of timing impact PHYOXX greater around the enrollment with in our extent have be to NDA plans, add move on ready people but once move that trial will have appropriate as
to antitrypsin or disease AXAT deficiency-associated now Turning program. alpha-X liver
Phase data the antitrust steps we our received our of analysis on will both the and FDA Alnylam inform which candidate, next from ALN-AATXX, AXAT designation begun the of dive and profile completed a in March. ALN-AATXX drug mid-April already now deeper orphan own evaluating the DCR-AXAT, have agreement which With in as help with I/II effective, and
development. We ALN-AATXX inform between selection DCR-AXAT term of better studies for and non-clinical ALN-AATXX to near the plan conduct to clinical our certain further in
to to testing. make I/II initiation patient prior expect a program the advance of cohorts only candidate the trial into to We and of one selection Phase the clinical patient
the I/II for we this As we to specifically to with for with candidate trial this the currently strongly development. disease. better believe subsequent to advancement clinical designed positioned AXAT, pivotal that condition, sufficient no have previously stated, to patients this we best Phase liver approved believe and treat therapies treat are our advance There be suited are we collaboration of will manifestations
result in current cohort. business update restrictions our a in continuing with as portion volunteers site for the DCR-AXAT COVID-XX ongoing of functionally Phase I/II follow-up Following the study from of March, enrollment healthy dosing arising of our was paused
of the encouraging we ago, About position the next be enrolling assuming is healthy enrollment. plan, there effect participant a week in for in dosing net only developments the will us are a cohort and in news weeks. screening with change the should no pace COVID next dosing new that, very by The begin the be volunteers to certain cohort that sites few received in gated next to
clarity for their DCR-AXAT, trial paramount remains continuation we participating for some we in safety additional and an our that taking on trial health. precautions those are in effort safeguard pleased While gaining to are
forward, receive augmentation AXAT As event levels in a COVID-like moves be And participant the COVID-XX post the symptoms trial with with they can diagnosed any is participants will therapy low. presenting are if their dosing, tested.
news, progress give DCR-AXAT date. of this we a and healthy or to timelines Despite dosing positive ALN-AATXX program trial patient the are the the monitor now, to updated for of guidance to provide situation, the portion completion plan on we'll initiation or DCR-AXAT, later but unable gauge our continue volunteers with either of at
that B hepatitis collaboration infection effectively, and infection, more our annually. Roche. disease cancer treated Now program than result RGXXXX third with GalXC-based liver advanced is serious turning RGXXXX, to a or which development liver treatment developing lives XXX,XXX claims are liver can we if chronic in a investigational in core virus for not that
We patients a study HBV. are Phase currently I with proof-of-concept conducting in
for agreed C treated RGXXXX. dose patients who new forgo four XX and As this RGXXXX; trial with to cohorts at was these composed last I of chronic diagnosed our HBV, three completed previously and to which A, with of who Group summarized naive comprises newly with received care and last are dose therapy in doses on year; ascending initiation of levels. NUCs groups: of B, patients volunteers, NUCs who received C, group patients group call, standard three healthy a in has group single of weeks,
XX and C. group XX the and group group end they X to B C study is or an antigen baseline are for for the if observation in eligible period, enter to weeks period achieve of surface than and reduction extended into of have Patients B which hepatitis follow-up formal B greater log reached equal weeks from
have multiple As the C. noted on B patients observation follow-up quarterly period, groups call, and entered representation both our including last extended from
three four group Note, two each with the treated consists and RGXXXX of patients of C placebo patients. cohorts
for per entered and participants Now is too cohort. milligram the specifically, milligram participants kilogram follow-up dose per X.X cohort kilogram It to four six dose this of out per milligram period. six X.X conditional in three in the out of X.X kilogram early say the cohort have
The the obviously, this milligram is per longest that of months the RGXXXX. kilogram And seven follow-up individual is after in at point last X.X dose cohort.
trial what receiving, but do said, know are treatment nonetheless the are regimen remains All we of by patients this blinded, observations. encouraged we and not these
The toward slower or up have patients study mean due and may formal read August will interim impacts. groups to XX C that the continues not for could period R&D to prior end two Day for we progress patients our study slightly of completion, pace to presentation. the B with that though planned the out at a This completed COVID-XX data three
and are combination not patients not studies these will of planned overall However, gating initiation impact program timelines. Roche's to
data showing first It will to our to tissues, first our forward be be and and data CNS. outside presentation new other liver at tissues the foremost, in Day the will our GalXC August platform are out it. the we our looking application planned R&D Rounding of presentation of
From has a standpoint, part quite year the collaboration been first of the productive.
in activities lab we during progress have essential remote have proceeded continued Our good worker collaborative make an under our to arrangements. work of and period, support this exemption mandatory
Lilly. First,
to well, first the advanced named with IND of now track CTA Lilly year for preclinical their the along second by Lilly GalXC remains has LYXXXXXXX. quarter to GalXC for candidate, of a candidate, their indication. moving also cardiometabolic Our collaboration their which or submit at Lilly with been the acceptance a development during end on LYXXXXXXX,
DCR-COMPX for and to acceptance and DCR-COMPX our triggered progression year manufacturing this development earlier the their Alexion's candidate clinical nominations preclinical of phase. Alexion. Second,
a Novo and Third, has with have while progress targets collaboration closed, few been literally initial it the is since selected. been just months our good agreement the making
research Ingelheim Fourth, on Boehringer track. with our discovery project remains
target the portion under And formally in also deepening first collaboration finally, nominated HBV. research of selected our our note to I'm today that has Roche agreement, the discovery pleased
to development receipt program Roche research to additional from collaboration I reminder, until of a targets a the to study As data and initiate select had HBV. RGXXXX Phase the related
and in engaged We are with GalXC pleased molecules. now portfolio of step Roche of next among them the new us with include partners take identification and this our to development collaborative
five development At have with efficiency this to underscoring drug and candidates. we we partners, GalXC speed point, turn the now can GalXC candidates delivered our which out new
COVID-XX are up To our us begin sum weeks programs, and our development that experienced allow have from we up, the nedosiran clinical pick cautiously and lift impacts although we the to programs. the in in some slowing to pace AXAT will on optimistic coming
to its enable we industry can headwinds of fortunate our some and impacts or to many have business model While and a weather situation direct are be the the to may that COVID-XX some yet soon sheet very future in time for others out, are balance place facing. financial have impacts globally play us now and that in
and key operate execute each evolution to well as on becoming our a before, us programs functions integrated we biopharmaceutical By positioning and execute of company. are the and resourcing toward goals, appropriately fully continuing large, to necessary in commercial-stage our
Before Jack announcement to retires our financials, our hiring discussion who the Doug our of succeeding Green Pagan, over for from Dicerna. Jack new I Officer, Chief I today want regarding call as turn he Financial will other a the be note to of
management. financial and and responsible led capital planning, biotechnology experience part development tax years organizations direction brings the was and from he reporting, than five more its SEC XX formation of as including treasury, investor biopharmaceutical traded transition strategic where company's at facilities commercial CFO Doug and publicly was stage for years relations, Paratek, to financial and and strategic overall and companies, finance, management of allocation, of IT
the background month will pleased us this a that of Doug at evolution. the strong skill sets fit and believe at in that and joining his for us very are end stage our be I'm
transition. quarterly communicated, and we leadership again remain to will once be Dicerna, will a thank call period smooth years. want until therefore, As last in previously Jack's dedication the This few joins, remain engaged an position for with he a steady had and over of past the CFO I will, ensure thereafter Doug his capacity to Jack and for time Jack in advisory
shoulder it's been work shoulder to privilege a with you. Jack, to
the CFO last Dicerna us wishes heartfelt for the at You've here colleagues successes congratulations in colleague and team that's speak had years. part my of and excellent an you to best I retirement. other we've a been can giving the all critical driven and thanks, few on your our
Jack?
